160 related articles for article (PubMed ID: 38589558)
1. Interaction of the chemotherapeutic agent oxaliplatin and the tyrosine kinase inhibitor dasatinib with the organic cation transporter 2.
Ahmed Eltayeb S; Dressler JM; Schlatt L; Pernecker M; Neugebauer U; Karst U; Ciarimboli G
Arch Toxicol; 2024 Jul; 98(7):2131-2142. PubMed ID: 38589558
[TBL] [Abstract][Full Text] [Related]
2. L-tetrahydropalmatine reduces oxaliplatin accumulation in the dorsal root ganglion and mitochondria through selectively inhibiting the transporter-mediated uptake thereby attenuates peripheral neurotoxicity.
Yi Y; Li L; Song F; Li P; Chen M; Ni S; Zhang H; Zhou H; Zeng S; Jiang H
Toxicology; 2021 Jul; 459():152853. PubMed ID: 34252480
[TBL] [Abstract][Full Text] [Related]
3. Relevance of copper transporter 1 and organic cation transporters 1-3 for oxaliplatin uptake and drug resistance in colorectal cancer cells.
Buß I; Hamacher A; Sarin N; Kassack MU; Kalayda GV
Metallomics; 2018 Mar; 10(3):414-425. PubMed ID: 29417972
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of OCT2, MATE1 and MATE2-K as a possible mechanism of drug interaction between pazopanib and cisplatin.
Sauzay C; White-Koning M; Hennebelle I; Deluche T; Delmas C; Imbs DC; Chatelut E; Thomas F
Pharmacol Res; 2016 Aug; 110():89-95. PubMed ID: 27178732
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory Effect of Crizotinib on Creatinine Uptake by Renal Secretory Transporter OCT2.
Arakawa H; Omote S; Tamai I
J Pharm Sci; 2017 Sep; 106(9):2899-2903. PubMed ID: 28336299
[TBL] [Abstract][Full Text] [Related]
6. Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2.
Sprowl JA; Ciarimboli G; Lancaster CS; Giovinazzo H; Gibson AA; Du G; Janke LJ; Cavaletti G; Shields AF; Sparreboom A
Proc Natl Acad Sci U S A; 2013 Jul; 110(27):11199-204. PubMed ID: 23776246
[TBL] [Abstract][Full Text] [Related]
7. Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2).
Burger H; Zoumaro-Djayoon A; Boersma AW; Helleman J; Berns EM; Mathijssen RH; Loos WJ; Wiemer EA
Br J Pharmacol; 2010 Feb; 159(4):898-908. PubMed ID: 20067471
[TBL] [Abstract][Full Text] [Related]
8. Investigations with Drugs and Pesticides Revealed New Species- and Substrate-Dependent Inhibition by Elacridar and Imazalil in
Kuehne A; Floerl S; Hagos Y
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555439
[TBL] [Abstract][Full Text] [Related]
9. Assessment of Substrate-Dependent Ligand Interactions at the Organic Cation Transporter OCT2 Using Six Model Substrates.
Sandoval PJ; Zorn KM; Clark AM; Ekins S; Wright SH
Mol Pharmacol; 2018 Sep; 94(3):1057-1068. PubMed ID: 29884691
[TBL] [Abstract][Full Text] [Related]
10. Modulating the Activity of the Human Organic Cation Transporter 2 Emerges as a Potential Strategy to Mitigate Unwanted Toxicities Associated with Cisplatin Chemotherapy.
Hucke A; Kantauskaite M; Köpp TN; Wehe CA; Karst U; Nedvetsky PI; Ciarimboli G
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474165
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effects of vandetanib on creatinine transport via renal organic cation transporter OCT2.
Tanihara Y; Masuda S; Inui KI
Eur J Pharm Sci; 2021 Mar; 158():105666. PubMed ID: 33296710
[TBL] [Abstract][Full Text] [Related]
12. Irinotecan Alters the Disposition of Morphine Via Inhibition of Organic Cation Transporter 1 (OCT1) and 2 (OCT2).
Zhu P; Ye Z; Guo D; Xiong Z; Huang S; Guo J; Zhang W; Polli JE; Zhou H; Li Q; Shu Y
Pharm Res; 2018 Oct; 35(12):243. PubMed ID: 30361780
[TBL] [Abstract][Full Text] [Related]
13. A phosphotyrosine switch regulates organic cation transporters.
Sprowl JA; Ong SS; Gibson AA; Hu S; Du G; Lin W; Li L; Bharill S; Ness RA; Stecula A; Offer SM; Diasio RB; Nies AT; Schwab M; Cavaletti G; Schlatter E; Ciarimboli G; Schellens JHM; Isacoff EY; Sali A; Chen T; Baker SD; Sparreboom A; Pabla N
Nat Commun; 2016 Mar; 7():10880. PubMed ID: 26979622
[TBL] [Abstract][Full Text] [Related]
14. Properties of Transport Mediated by the Human Organic Cation Transporter 2 Studied in a Polarized Three-Dimensional Epithelial Cell Culture Model.
Koepp TN; Tokaj A; Nedvetsky PI; Conchon Costa AC; Snieder B; Schröter R; Ciarimboli G
Int J Mol Sci; 2021 Sep; 22(17):. PubMed ID: 34502566
[TBL] [Abstract][Full Text] [Related]
15. Proguanil and cycloguanil are organic cation transporter and multidrug and toxin extrusion substrates.
van der Velden M; Bilos A; van den Heuvel JJMW; Rijpma SR; Hurkmans EGE; Sauerwein RW; Russel FGM; Koenderink JB
Malar J; 2017 Oct; 16(1):422. PubMed ID: 29061131
[TBL] [Abstract][Full Text] [Related]
16. 3D-QSAR analysis of the interactions of flavonoids with human organic cation transporter 2.
Bi Y; Wang X; Li H; Tian Y; Han L; Gui C; Zhang Y
Toxicol Lett; 2022 Sep; 368():1-8. PubMed ID: 35901987
[TBL] [Abstract][Full Text] [Related]
17. Organic cation transporter 2 activation enhances sensitivity to oxaliplatin in human pancreatic ductal adenocarcinoma.
Chiu CF; Park JM; Chen HH; Mau CZ; Chen PS; Su YH; Chen HA; Liu YR; Hsieh TH; Chiu CC; Hung SW; Kuo CY; Chen YM; Chang CF
Biomed Pharmacother; 2022 Sep; 153():113520. PubMed ID: 36076515
[TBL] [Abstract][Full Text] [Related]
18. Targeting OCT2 with Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neurotoxicity.
Nepal MR; Taheri H; Li Y; Talebi Z; Uddin ME; Jin Y; DiGiacomo DF; Gibson AA; Lustberg MB; Hu S; Sparreboom A
Cancer Res Commun; 2022 Nov; 2(11):1334-1343. PubMed ID: 36506732
[TBL] [Abstract][Full Text] [Related]
19. Substrate-Dependent
Lefèvre CR; Le Vée M; Gaubert S; Jouan E; Bruyere A; Moreau C; Fardel O
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884730
[TBL] [Abstract][Full Text] [Related]
20. Substrate-Dependent Inhibition of the Human Organic Cation Transporter OCT2: A Comparison of Metformin with Experimental Substrates.
Hacker K; Maas R; Kornhuber J; Fromm MF; Zolk O
PLoS One; 2015; 10(9):e0136451. PubMed ID: 26327616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
